Neuraxon, Inc.
Records under this name other than patents Neuraxon, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,106,043 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity Lapsed on the fee record Ended Jan 31, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 31, 2024 | From the USPTO record |
| US 7,951,940 | Substituted indole compounds having NOS inhibitory activity Lapsed on the fee record Ended May 31, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 31, 2023 | From the USPTO record |
| US 8,673,909 | Indole compounds and methods for treating visceral pain Lapsed on the fee record Ended Mar 18, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 18, 2022 | From the USPTO record |
| US 7,375,219 | Substituted Indole Compounds Having Nos Inhibitory Activity Lapsed on the fee record Ended May 20, 2020 · High confidence | Lapsed on the fee record | Ended May 20, 2020 | High confidence |
| US 8,173,813 | Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity Lapsed on the fee record Ended May 8, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 8, 2020 | From the USPTO record |
| US 6,284,794 | Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase Term ended Term ended May 4, 2019 · From the USPTO record | Term ended | Term ended May 4, 2019 | From the USPTO record |
| US 8,618,286 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity Lapsed on the fee record Ended Dec 31, 2017 · From the USPTO record | Lapsed on the fee record | Ended Dec 31, 2017 | From the USPTO record |
| US 8,586,620 | Substituted indole compounds having NOS inhibitory activity Lapsed on the fee record Ended Nov 19, 2017 · From the USPTO record | Lapsed on the fee record | Ended Nov 19, 2017 | From the USPTO record |
| US 6,649,605 | Treatment of tension-type headaches with NMDA receptor antagonists Lapsed on the fee record Ended Nov 18, 2015 · From the USPTO record | Lapsed on the fee record | Ended Nov 18, 2015 | From the USPTO record |
| US 7,989,447 | 1,5 and 3,6- Substituted Indole Compounds Having Nos Inhibitory Activity Formerly held Lapsed on the fee record Ended Aug 2, 2015 · High confidence | Lapsed on the fee record | Ended Aug 2, 2015 | High confidence |